State Street Increases Position in BioCryst Pharmaceuticals (BCRX) | CPT PPP Coverage
Cryptopolytech (CPT) Public Press Pass (PPP)
News of the Day COVERAGE
200000048 – World Newser
•| #World |•| #Online |•| #Media |•| #Outlet |
View more Headlines & Breaking News here, as covered by cryptopolytech.com
State Street Increases Position in BioCryst Pharmaceuticals (BCRX) appeared on www.nasdaq.com by Nasdaq.
Fintel reports that State Street
has filed a 13G/A form
with the SEC disclosing ownership of
11.13MM
shares of BioCryst Pharmaceuticals, Inc. (BCRX).
This represents 5.97% of the company.
In their previous filing dated February 9, 2022
they reported 8.25MM shares and 4.58% of the company,
an increase in shares of 34.89%
and
an increase in total ownership of
1.39% (calculated as current – previous percent ownership).
Analyst Price Forecast Suggests 52.54% Upside
As of February 5, 2023,
the average one-year price target for BioCryst Pharmaceuticals is $16.09.
The forecasts range from a low of $10.10 to a high of $31.50.
The average price target represents an increase of 52.54% from its latest reported closing price of $10.55.
The projected annual revenue for BioCryst Pharmaceuticals
is $363MM, an increase of 52.34%.
The projected annual EPS
is $-0.86.
Fund Sentiment
There are 445 funds or institutions reporting positions in BioCryst Pharmaceuticals.
This is a decrease
of
6
owner(s) or 1.33%.
Average portfolio weight of all funds dedicated to US:BCRX is 0.2217%,
an increase
of 8.5216%.
Total shares owned by institutions decreased
in the last three months by 1.87% to 162,761K shares.
What are large shareholders doing?
Baker Bros. Advisors
holds 12,710,818 shares
representing 6.82% ownership of the company.
No change in the last quarter.
Avoro Capital Advisors
holds 9,050,000 shares
representing 4.85% ownership of the company.
In it’s prior filing, the firm reported owning 6,500,000 shares, representing
an increase
of 28.18%.
The firm
increased
its portfolio allocation in BCRX by 55.02% over the last quarter.
XBI – SPDR Biotech ETF
holds 5,645,990 shares
representing 3.03% ownership of the company.
In it’s prior filing, the firm reported owning 7,314,670 shares, representing
a decrease
of 29.56%.
The firm
decreased
its portfolio allocation in BCRX by 7.97% over the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares
holds 5,588,361 shares
representing 3.00% ownership of the company.
In it’s prior filing, the firm reported owning 5,465,862 shares, representing
an increase
of 2.19%.
The firm
increased
its portfolio allocation in BCRX by 26.92% over the last quarter.
Pictet Asset Management
holds 4,813,772 shares
representing 2.58% ownership of the company.
In it’s prior filing, the firm reported owning 6,046,961 shares, representing
a decrease
of 25.62%.
The firm
decreased
its portfolio allocation in BCRX by 46.40% over the last quarter.
Biocryst Pharmaceuticals Background Information
(This description is provided by the company.)
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
FEATURED ‘News of the Day’, as reported by public domain newswires.
View ALL Headlines & Breaking News here.
Source Information (if available)
This article originally appeared on www.nasdaq.com by Nasdaq – sharing via newswires in the public domain, repeatedly. News articles have become eerily similar to manufacturer descriptions.
We will happily entertain any content removal requests, simply reach out to us. In the interim, please perform due diligence and place any content you deem “privileged” behind a subscription and/or paywall.
CPT (CryptoPolyTech) PPP (Public Press Pass) Coverage features stories and headlines you may not otherwise see due to the manipulation of mass media.
First to share? If share image does not populate, please close the share box & re-open or reload page to load the image, Thanks!